Your browser is no longer supported. Please, upgrade your browser.
BCEL Atreca, Inc. daily Stock Chart
Atreca, Inc.
Index- P/E- EPS (ttm)-2.19 Insider Own17.30% Shs Outstand22.27M Perf Week43.96%
Market Cap318.68M Forward P/E- EPS next Y-2.60 Insider Trans0.00% Shs Float14.58M Perf Month9.32%
Income-59.40M PEG- EPS next Q-0.64 Inst Own86.20% Short Float4.36% Perf Quarter-2.19%
Sales- P/S- EPS this Y-37.80% Inst Trans1.53% Short Ratio5.37 Perf Half Y-
Book/sh7.33 P/B1.95 EPS next Y24.90% ROA- Target Price28.20 Perf Year-
Cash/sh9.03 P/C1.59 EPS next 5Y- ROE- 52W Range9.51 - 23.65 Perf YTD-20.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.49% Beta-
Dividend %- Quick Ratio27.40 Sales past 5Y- Gross Margin- 52W Low50.47% ATR1.44
Employees102 Current Ratio27.40 Sales Q/Q- Oper. Margin- RSI (14)70.86 Volatility24.53% 10.85%
OptionableNo Debt/Eq0.00 EPS Q/Q-57.80% Profit Margin- Rel Volume3.00 Prev Close14.47
ShortableYes LT Debt/Eq0.00 EarningsNov 12 Payout- Avg Volume118.31K Price14.31
Recom1.70 SMA2029.13% SMA5029.22% SMA2004.45% Volume343,467 Change-1.11%
Sep-04-19Initiated ROTH Capital Buy $30
Jul-15-19Initiated Stifel Buy $28
Jul-15-19Initiated Evercore ISI Outperform
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated Canaccord Genuity Buy $23
Dec-03-19 08:00AM  Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101 GlobeNewswire +32.34%
Nov-14-19 08:00AM  Atreca to Present at Two Upcoming Investor Conferences GlobeNewswire
Nov-12-19 04:05PM  Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Nov-05-19 08:00AM  Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Sep-19-19 09:19AM  Do Institutions Own Shares In Atreca, Inc. (NASDAQ:BCEL)? Simply Wall St.
Aug-26-19 04:05PM  Atreca Announces Appointment of Dr. Lindsey Rolfe to its Board of Directors GlobeNewswire -6.49%
Aug-17-19 07:30AM  Stanford University Now Owns Stakes in Uber and Pinterest Stock
Aug-13-19 04:05PM  Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire +25.78%
Jul-15-19 02:22PM  Stifel: Atreca Offers Attractive Oncology Drug Development Play Benzinga
Jul-11-19 08:00AM  Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel GlobeNewswire
Jun-20-19 11:16AM  Atreca Opens For Trade Benzinga
Jun-19-19 09:40PM  Atreca Announces Pricing of Initial Public Offering GlobeNewswire
08:20AM  Atreca IPO: What You Need To Know Benzinga
Jun-17-19 10:07AM  IPO Outlook For The Week: Biotechs And A Grocery Outlet Benzinga
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.